Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

Inclusion Criteria Patients must have: Asymptomatic HIV infection. CD4 count 100-400 cells/mm3. No HIV-associated neurologic abnormalities or constitutional symptoms. No oral hairy leukoplakia. At least 6 months of prior AZT. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Abnormal chest x-ray, consistent with active opportunistic infection. Hypersensitivity to thymopentin. Significant chronic underlying medical illness. Grade 2 or worse peripheral neuropathy. Concurrent Medication: Excluded: HIV vaccines. Investigational or non-FDA approved medication. Immunomodulatory therapies. Experimental therapies. Any antiretroviral therapy other than AZT, ddI, ddC, d4T, or 3TC. Patients with the following prior conditions are excluded: Herpes zoster (within the past year). Recurrent (> one episode) oral candidiasis (confirmed). Vulvovaginal candidiasis (persistent, frequent, or poorly responsive to therapy). Bacillary angiomatosis. Listeriosis. Idiopathic thrombocytopenia purpura. Prior Medication: Excluded at any time prior to study entry: More than one dose of thymopentin. Excluded within 30 days prior to study entry: HIV vaccines. Investigational or non-FDA approved medication. Immunomodulatory therapies. Experimental therapies. Any antiretroviral therapy other than AZT, ddI, ddC, d4T, or 3TC. Required: Prior AZT (>= 300 mg/day) for at least 6 months; on current regimen (any combination of approved nucleoside analogues) for at least 4 weeks. Significant active alcohol or drug abuse.